Researchers identified distinct patterns of cardiac troponin distribution between extracellular vesicles and free plasma that can differentiate myocardial infarction from arrhythmia-induced heart injury. Testing cardiomyocytes, animal models, and two patient cohorts, they found that the relative fraction of troponin bound to extracellular vesicles provides disease-specific signatures that robustly discriminate between ischemic and non-ischemic cardiac conditions. This discovery addresses a critical clinical challenge where elevated troponin levels often trigger invasive diagnostic procedures to rule out heart attacks, even when the elevation stems from non-ischemic causes like arrhythmias. The EV-troponin fraction could transform emergency cardiology by providing more precise diagnostic information from a simple blood test. Currently, any troponin elevation raises concern for myocardial infarction, leading to potentially unnecessary catheterizations and prolonged hospitalizations. This biomarker approach could reduce healthcare costs and patient anxiety while improving diagnostic accuracy. However, this preprint awaits peer review, and the findings require validation in larger, diverse patient populations before clinical implementation. The work represents a potentially paradigm-shifting advance in cardiovascular diagnostics, offering a more nuanced understanding of troponin biology beyond simple elevation detection.